Publications
Atypical Hemolytic Uremic Syndrome
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis
in factor H-deficient mice. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y,
Walport MJ, Cook HT, Botto M. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9649-54.
Asthma
Role of C5 in the development of airway inflammation, airway hyper-responsiveness,
and ongoing airway response. Peng T, Hao L, Madri JA, Su X, Elias JA, Stahl GL,
Squinto S, Wang Y. J Clin Invest. 2005 Jun;115(6):1590-600.
Cancer
Blockade of CD200 in the presence or absence of antibody effector function: implications
for anti-CD200 therapy. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ,
Bowdish KS. J Immunol. 2008 Jan 15;180(2):699-705.
CD200 expression on tumor cells suppresses antitumor immunity: new approaches to
cancer immunotherapy. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter
J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ, Wu D, Springhorn J,
Bowdish KS. J Immunol. 2007 May 1;178(9):5595-605.
Neurology
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC,
Rother RP, Plomp JJ, Willison HJ. Brain. 2008 May;131(Pt 5):1197-208.
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia
gravis. Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. J Immunol. 2007
Dec 15;179(12):8562-7.
PNH
Expression of Recombinant Transmembrane CD59 in Paroxysmal Nocturnal Hemoglobinuria
B Cells Confers Resistance to Human Complement. Rother RP, Rollins SA, Mennone J,
Chodera A, Fidel SA, Bessler M, Hillmen P, and Squinto SP. Blood, Vol84, No 8 (October
15). 1994: pp 2604-2611.
See additional
publications on PNH.
Transplantation
C5 blockade with conventional immunosuppression induces long-term graft survival
in presensitized recipients. Rother RP, Arp J, Jiang J, Ge W, Faas SJ, Liu W, Gies
DR, Jevnikar AM, Garcia B, Wang H. Am J Transplant. 2008 Jun;8(6):1129-42.
Inhibition of terminal complement components in presensitized transplant recipients
prevents antibody-mediated rejection leading to long-term graft survival and accommodation.
Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, Ramcharran S, Garcia B, Zhong R,
Rother RP. J Immunol. 2007 Oct 1;179(7):4451-63.
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal
antibody combined with cyclosporine. Wang H, Jiang J, Liu W, Kubelik D, Chen G,
Gies D, Garcia B, Zhong R, Rother RP. Transplantation. 2005 May 15;79(9):1121-7.
Anti-C5 antibodies
Inhibition of complement activity by humanized anti-C5 antibody and single-chain
Fv. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH,
Matis LA, Squinto SP, Evans MJ. Mol Immunol. 1996 Dec;33(17-18):1389-401.
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment
recognizing human C5. Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien
DM, Grijalva GA, Mueller JP, Nye SH, Squinto SP, et al. Mol Immunol. 1995 Nov;32(16):1183-95.
Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, Rollins
SA. Nat Med. 1995 Aug;1(8):839-42.